secwatch.observer — SEC 8-K summary
======================================

Issuer:     Entrada Therapeutics, Inc. (TRDA)
CIK:        0001689375
Form:       8-K
Filed at:   2023-08-01T23:59:59+00:00
Accession:  0001104659-23-086035
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Entrada Therapeutics gets UK authorization to start Phase 1 trial of ENTR-601-44 for Duchenne
--------------------------------------------------------------------------------

- UK MHRA and REC authorized Phase 1 CTIMP for ENTR-601-44 in healthy volunteers for exon 44 skipping Duchenne.
- Phase 1 will enroll ~40 participants; primary endpoint safety, plus tolerability, PK, and exon skipping in muscle.
- First participant expected to be dosed September 2023; data anticipated in second half of 2024.
- Cash runway extended through end of 2025, supporting Duchenne franchise and broader intracellular therapeutics.
- ENTR-601-44 is lead Duchenne product candidate for patients amenable to exon 44 skipping.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1689375/000110465923086035/0001104659-23-086035-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1689375/000110465923086035/tm2322453d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-086035

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer